OVERVIEW

Follistatin‑344 1 mg is a synthetic form of follistatin, a naturally occurring glycoprotein that regulates members of the transforming growth factor‑beta (TGF‑β) superfamily, particularly myostatin and activins, which are important negative regulators of muscle growth. Follistatin‑344 is a shorter isoform compared with follistatin‑315, with a truncated C-terminal sequence that influences its distribution and binding characteristics. In preclinical studies, increasing levels of follistatin‑344 has been associated with inhibition of myostatin signaling, which can lead to enhanced muscle fiber growth, improved muscle regeneration, and accelerated recovery after injury. Because myostatin normally limits muscle mass, follistatin‑344’s ability to block its activity has made it a focus of research in muscle wasting disorders, regenerative biology, and performance-related studies. Laboratory models have shown that this peptide can promote anabolic pathways in skeletal muscle, making it of interest for experimental exploration of muscle hypertrophy and repair.

Despite promising preclinical findings, Follistatin‑344 1 mg is not approved for therapeutic or human use by the U.S. Food and Drug Administration or other major regulatory agencies. Evidence in humans is extremely limited, and most research comes from animal studies or in vitro experiments. Products sold with this peptide are typically labeled for research use only, and purity, quality, and dosing consistency are not regulated to pharmaceutical standards. Self-administration outside controlled research environments carries potential safety, ethical, and legal risks. Individuals seeking muscle growth or recovery should rely on evidence-based interventions and consult qualified healthcare professionals rather than unregulated peptides.